Page 2 - J Amp News Today

The settlement would avert potential lawsuits alleging Johnson & Johnson hid any links between the talc in its powder and various cancers, Bloomberg News reported on Monday

In the last month, there has been a flurry of activity at the PTAB related to challenges from biosimilar manufacturers related to ustekinumab, aflibercept, and eculizumab patents.

The abstracts, made available Tuesday ahead of the European Society for Medical Oncology Congress 2023, show strong efficacy data from some promising non-small cell lung cancer treatments.

The superior court of New Jersey, appellate division found a lower court judge should not have allowed some of the scientific expert testimony the plaintiffs presented to jurors at trial.

Kaiser Permanente workers strike; CDC proposes a new policy to decrease sexually transmitted infection (STI) cases; New Jersey court tosses $223.8 million decision against J&J in talc cancer case.

Alberta’s information watchdog opens systemic probe into ministries’ handling of access requests

Drug manufacturer agrees not to enforce its patents on a tuberculosis drug in 134 low- and middle-income countries

The published version of Forbes Future of Work newsletter delivers the latest news for chief human resources officers and other talent managers on disruptive technologies, managing the workforce and trends in the remote work debate to your inbox every Friday.

A South African commission is investigating Johnson & Johnson for the high price of its TB drug and its decision to prolong its patent in the country

Health care giant Johnson & Johnson is unveiling a new logo to reflect its focus on pharmaceuticals and medical devices. The new logo will replace the script used since 1887 and will feature a modern design with a different shade of red. The original script will still be used on consumer products from Kenvue, a company recently spun off from J&J.